The aim of the study was to assess the efficacy and adverse effect profile of each individual AED by analysing all available data published and then evaluating how reliable it was.
The researchers gathered, screened and assessed all the information published in peer-reviewed journals and publications. The individual studies were then evaluated based on the quality of evidence, study design, study group sizes, subject enrolment quality and overall risk of bias, as well as the efficacy and safety outcome measures.
Lead-author, Marios Charalambous from Ghent University, said: "We recruited systematic methods to combine, compare and summarise the results of independent studies and, therefore, create more objective and reliable conclusions based on the current evidence. It was a time-consuming, demanding and challenging process, and we hope we provided the clinicians now with essential information which they can use for daily practice."
The researchers found that much of the evidence for the medical treatment of feline epilepsy was based on below-par reporting of efficacy and adverse effect, worse than what was formerly reported in dogs.
The lack of good quality evidence led authors to conclude that it would be: "...rather inaccurate to make definite statements on which one [AED] should be considered as a first or second choice in terms of both efficacy and safety profile. However, if clinicians focus on AED’s efficacy, phenobarbital can be used as first-choice monotherapy and if they focus on AED’s safety, imepitoin or levetiracetam can be used."
Holger Volk, Head of the Department Clinical Science and Services and Professor of Veterinary Neurology and Neurosurgery at the RVC, said: "Not only does this study offer a new perspective on the management of feline epilepsy, but also highlights the importance of the need for trials which provide high quality evidence in order to have more reliable and objective results about the efficacy and safety of the AEDs in feline epilepsy."
The study was published in BMC Veterinary Research (https://doi.org/10.1186/s12917-018-1386-3).
The practice is one of few in the UK to use radioactive iodine (RAI) therapy, which, it says, has an average, a 95% success rate in treating cats with hyperthyroidism.
Stephanie Lalor MRCVS (pictured right), an RCVS Specialist in Feline Medicine at Willows said: "The new therapy is non-invasive and is the gold standard of treatment for cats with hyperthyroidism. It is safe and highly effective and a single injection can be curative. Patients do need to be screened for their suitability and ideally they are treated with medical therapy prior to the RAI.
"Due to the radioactive nature of the treatment, patients must stay with us for 15 days after the injection. Our patients stay in luxury cat condos during their hospitalisation and their day-to-day care is over-seen by our lead radioactive iodine nurse, Vicky Maund."
The new unit is part of a £1 million investment in Willows which includes a dedicated operating theatre for minimally invasive procedures, a range of specialist treatment rooms and more than 40 new kennels.
Toby Gemmill, clinical director at Willows, said: "We are already extremely well placed to offer a wide variety of specialist treatments and this extension has provided us with the space to expand our services further. The new radioactive iodine unit is very exciting and allows us to build on our gold level cat-friendly clinic status."
For more information, visit www.willows.uk.net.
Dr Neil Bryant from the AHT, who is leading the research, said: "EHV is a major welfare concern for horses and foals and causes emotional, as well as financial strains, on horse owners and breeders around the world. It can strike any horse at any time so a vaccine will be of global welfare benefit to all horses, including the thoroughbred and sports horse breeding industries, and would help control this serious and sometimes fatal disease."
As a viral infection, EHV can cause respiratory disease, abortion or fatal illness in new born foals and neurological disease in adult horses, with signs ranging from slight wobbliness through to complete paralysis. The disease can strike any horse at any time because the virus, like other herpesviruses (such as the cold sore virus in humans), becomes dormant within most horses early in their life. It then re-emerges when the animal is later stressed such as when transported or mixed with new horses. A seemingly healthy pregnant mare may suddenly, and without warning, abort her unborn foal or may show signs of respiratory disease including mild fever, coughing and discharge from the nose. A horse which appears fit and well may suddenly show abnormalities when walking and within hours may be unable to stand.
Despite the potential severity and impact of outbreaks, there is still no vaccine that is licensed to protect against the neurological form of the disease and abortions still occur in highly vaccinated horse populations. The AHT says protection afforded by existing vaccines currently in use is sub-optimal, something that was highlighted by the 2016 abortion storm in Hertfordshire in fully vaccinated animals.
Neil added: "We have become aware of a pressing need for progress towards a new and improved EHV-1 vaccine. Just last month, the AHT was again called upon to work with the racing industry and affected parties in dealing with confirmed cases of EHV-1 abortion in premises in Yorkshire and Suffolk."
To that end, the charity has now established the Equine Industries EHV Vaccine Steering Group. Chaired by Professor Joe Brownlie of the RVC, the steering group includes world-renowned experts on both human and equine herpes viruses from a number of research establishments, who have concluded that the most appropriate way forward is for the AHT to design a modified live virus (MLV) vaccine.
After securing funding from a large number of organisations, including the Alborada Trust, EBM Charitable Trust, Horserace Betting Levy Board and the Racing Foundation, Paul Mellon Estate, Thompson Family Charitable Trust, Coolmore Ireland, Newsells Park Stud, Thoroughbred Breeders’ Association and Juddmonte Farms, the AHT has begun its five-year research programme.
Neil added: "We’re at the beginning of a very exciting and potentially ground-breaking vaccine development. Through our research, we will construct different viruses with attenuating mutations and assess their suitability as MLVs. We hope our findings will enable further development by vaccine manufacturers in creating an effective vaccine to protect against the serious clinical signs induced by EHV-1."
"We would like to reassure vets, and through them dog owners, that we are constantly reviewing adverse event report data to ensure that the benefits of each UK licenced veterinary medicine product outweighs the risk posed by their potential side-effects.
There are a number of vaccines authorised in the UK containing either two (L2) or four (L4) strains of Leptospira. Based on the most recent periodic safety update report data received for each product, the incidence of adverse animal reactions for all L2 vaccine products combined is 0.015%; for L4 vaccine products this figure is 0.069%.
In other words, the VMD has received fewer than 2 adverse reactions for L2, and fewer than 7 for L4, for every 10,000 doses sold. This includes every suspected adverse event reported, even cases that were considered unclassifiable or were later found to be unrelated to the vaccine.
The overall incidence of suspected adverse reactions for both L2 and L4 vaccine products is therefore considered to be rare."
It is hoped the survey will capture the experiences vets have had reporting ADRs, as well as identifying barriers to the current process which could be used to improve the ease with which ADRs are reported in the future.
PhD student Heather Davies (pictured right), who is leading the research project, said: "The survey is an important opportunity to gain insights into the issues that vets face when dealing with ADRs.
"We want to make the process easier in order to improve the safety of veterinary medicines, and ultimately, we need the help of professionals on the front line in order to do that."
She added: "The survey is relatively short and can be completed anonymously.
"We’re really keen to gather as many of your experiences as possible so we’d like to encourage veterinary professionals to complete it."
The research is being carried out as part of a PhD project funded by the Veterinary Medicines Directorate (VMD) in collaboration with the Small Animal Veterinary Surveillance Network (SAVSNET), based at the university.
The survey is now open and you can take part here: https://liverpool.onlinesurveys.ac.uk/adrs-vet
Any questions about the survey can be addressed directly to the researchers: Heather Davies (PhD student): H.H.Davies@liverpool.ac.uk and/or Dr David Killick (Supervisor): David.Killick@liverpool.ac.uk.
The RCVS Disciplinary Committee has dismissed charges of serious professional misconduct against a veterinary surgeon and former employee of Medivet (Watford).
Tomasz Nazimek, who qualified in Poland in 2001 before starting work in England in 2005, was alleged to have charged for the use of a blood pressure monitor during an exploratory laparotomy on a cat called Mitzi, whilst working at the Watford branch of Medivet in June 2009, when he knew, or ought to have known, it had not been used.
Despite his previous signed statements to the contrary, Mr Nazimek admitted at the outset of the hearing that no blood pressure monitor had in fact been used.
Accordingly, the Committee only had to establish whether Mr Nazimek himself had entered the fee for its use into Mitzi's records and, if so, whether this was done dishonestly.
The alleged incident came to light as a result of a covert investigation into Medivet conducted by the television production company Fulcrum TV in 2008/9, and subsequently commissioned by the BBC and broadcast in July 2010 as part of the Panorama programme 'It Shouldn't Happen at a Vets''.
Former dental nurse Alexandra Lee was employed by Fulcrum TV as an undercover reporter to work as a 'trainee veterinary nurse' at Medivet, in order to record audio and video footage of her experiences there.
The case against Mr Nazimek was based partly on a conversation overheard by Miss Lee following the operation on Mitzi, where she maintained that Guy Carter, a senior Medivet partner and veterinary surgeon, told Mr Nazimek (who was sitting at the practice computer typing up Mitzi's records) not to forget to include a fee for use of the blood pressure monitor.
However, Miss Lee's equipment had not recorded this exchange, due to a fault, and her video diary of that day's events was not put in evidence before the Committee. Miss Lee also accepted in evidence that she had not actually seen who entered the fee into the records, but had assumed it was Mr Nazimek.
Despite giving serious consideration to all of Miss Lee's evidence, the Committee found it of limited value.
The Committee considered the statements signed by Mr Nazimek, but prepared for him by the Medivet senior management in December 2009 and October 2010, which stated that he had used the monitor, consulted Mr Carter about charging for it and then added the fee himself.
The Committee also considered a third statement provided to the College (September 2011), in which Mr Nazimek recalled that Mr Carter had priced up the operation himself, but not asked for his input.
When questioned about the discrepancies in his statements, Mr Nazimek told the Committee that he had confused different operations and now knew his earlier statements to be wrong.
He indicated that he had been under pressure from his then employers to sign the statements, that his attempts to change them were ignored by Medivet's managing partners and that he was depressed and under stress at the time.
He was not told that the statements could be in relation to charges against him, or that he was entitled to legal advice when discussing them with his employers.
The Committee found Mr Nazimek's oral evidence to be persuasive, his manner open and his responses under cross-examination frank.
In the absence of satisfactory and reliable evidence to the contrary, and in view of supportive testimonials provided from his current employer and former colleagues as to his honesty and integrity, the Committee found Mr Nazimek's repeated assertion that he did not make a charge for the monitor "entirely plausible" and believed that he told the truth.
Nevertheless, the Committee emphasised that a charge for the monitor had been entered into the records when no such device had been used, which it regarded as unacceptable.
Speaking on behalf of the Committee, Chairman Professor Peter Lees said: "The Committee is not satisfied by the evidence so that it is sure that [Mr Nazimek] entered into the records for Mitzi a charge for the blood pressure monitor. [It] believes that [Mr Nazimek] told the truth when giving his evidence and the character references support his honesty.
"In these circumstances, it is not necessary to consider the charges further and the allegations against [Mr Nazimek] are dismissed."
Virbac points to how the pandemic has caused a fundamental shift in consumer shopping habits, with e-commerce accounting for more than 30% of retail sales in the UK in 2020 for the first time1.
Alongside the increase in online sales has come an expectation by consumers that all companies should provide a reliable digital service, with 70% saying that they will continue to buy essential goods online post-pandemic2.
At the same time, sales of pet food in the majority of veterinary practices have been hit by the need for social distancing.
Through the new model, when pet owners buy Virbac's low-carb, high protein Veterinary HPM dog and cat food from the company's new web store for home delivery, a commission is paid to the practice.
Remi Mandray, Product Manager at Virbac said: "It’s a win-win for our practices and their clients, who can take advantage of this convenient option to have their pet food delivered to their home, whilst providing the practice with a protected and rewarding business model".
For more information, contact your Virbac Territory Manager.
References
The 'Room For Rabbits' campaign follows research in which 38% of vets said they think rabbits’ environment is the most neglected welfare need1, with over a quarter of the UK’s rabbits being kept in inadequate housing conditions, and almost half of them living alone2.
The RAW survey also found that 90% of vets believe that rabbits’ welfare in the UK is improving3.
Room for Rabbits will throw a spotlight on rabbits’ environment, with a variety of initiatives during RAW including vet blogs and videos on how to adapt bunnies’ housing for all seasons, boredom buster ideas, a competition to encourage owners to create a RAW ‘gold standard’ environment, and downloadable packs containing resources for practices to create their own RAW campaigns.
Holly Castle, Senior Brand Manager at Burgess Pet Care, RAAG member and organisers of RAW, said: “We are delighted that RAW continues to have a positive impact, with our survey showing that 90% of vets believe that the welfare of the UK’s rabbits is improving - but there is always more than we can do.
“Since the previous RAW campaign, we have successfully launched RAAG, which recognises that the welfare of these wonderful creatures needs to be high on the agenda year-round.
"By bringing together the expertise of the RAW partners, RAAG is focused on encouraging everyone involved with rabbits to support the first Good Practice Code for rabbits’ welfare in England to ensure it becomes enshrined in law.
"One of the ways to achieve this is through initiatives like RAW, which is the UK’s largest welfare campaign of its kind.
“We recognise that vets’ practices were really stretched last year due to the Covid-19 pandemic, which meant it was difficult to support campaigns like RAW.
"However, following a surge in demand for rabbit ownership in the UK during the past two years, it is vitally important that we educate more owners than ever before and continue to help improve rabbits’ welfare."
“The veterinary community plays a hugely important role in ensuring that owners have access to the right information, and we are urging practices to throw their support behind this year’s RAW to ensure that we reach as many owners as possible.
Professor Ian Ramsey, Past President of the BSAVA, which endorses RAW, said: "The BSAVA is once again delighted to support RAW and the theme of this year’s campaign.
"Rabbits remain one of the most misunderstood pets in the UK, but we are confident that vets across the UK will again show their support for this important campaign to improve the lives of pet rabbits.”
The RAAG is encouraging vets’ practices to sign up to receive updates about RAW at https://www.rabbitawarenessactiongroup.co.uk/raw-pack-reminder/.
Downloadable RAW vet packs will also be available from 6th June.
BVA President Malcolm Morley said: “Judging this competition has been genuinely both extremely enjoyable and really difficult.
"The entries this year have absolutely surpassed expectations and the level of talent on display is amazing.
"However, the photographs we have chosen are all well worthy of being finalists.
"From photos that made us laugh out loud, to others that made some of us feel close to tears, they evoked a range of emotions, but we were also impressed by the quality of the images, the creativity of the photographers and the composition of the photos, as well as the stories behind the lens.
The finalists are:
Vets at work
All creatures great and small
Happy pets that make us smile
The winners will be announced at BVA Live at Birmingham’s NEC in May, where this year there is also an opportunity for BVA Live delegates to vote for their favourite image from the shortlist, with a new ‘People’s Choice’ winner being announced in the weeks following the event.
The WellVet Weekend will include a variety of sporting activities, yoga classes, wellbeing workshops and social times, all finished off with a gala dinner. Something for everyone.
Speaking at the gala dinner on the Saturday evening will be Rob Pope. Rob, also known as the 'real-life Forrest Gump' is an emergency vet by night and a marathon runner by day. He's the first person ever to run across the USA four times in one year and he's currently running across the USA for the fifth time. This will be Rob’s first public event following his completion of this epic journey.
Liz Barton, Founder of Vetsnet said: "I love sport and I love this profession, so it's fantastic to be able to organise a weekend dedicated to the physical and mental wellbeing of vets and vet nurses. It promises to be a brilliant weekend, and I’m excited to have Rob Pope join us to share his stories from the road."
Ru Clements, Founding Partner of VetLed said: "We’re excited to create a community which supports veterinary professionals to thrive. The WellVet Weekend is a very special concept with a core mission that we wholeheartedly believe in. We hope we can make a long-lasting positive difference to those who attend the first WellVet Weekend."
For more information and to buy your ticket, visit www.wellvet.co.uk
Maprelin, which contains a new active molecule, Peforelin, is a gonadotropin releasing hormone (GnRH). A single, low volume injection of the ready-to-use solution induces oestrus in sows after weaning, and in sexually mature gilts where oestrus has been synchronised with Regumate Porcine.
According to the company, it works by selectively inducing the release of the animal's own follicle stimulating hormone (FSH), leading to follicle growth - critical to successful reproduction - and the stimulation of oestrus. Conventional GnRHs, because of their mode of action, are used mainly to induce ovulation.
Janssen says Maprelin is the next step in its pig reproduction programme, named Syncoris. Cornerstone of this programme is Regumate for gilt synchronisation.
Trials have shown that with the use of Maprelin (compared with control groups of breeding animals) the number of gilts and sows showing oestrus within six days of treatment increased by about 15 percentage points (Table 1). For first-litter sows the figure was more than 8 percentage points. The duration of oestrus was not affected.
Gilts came on heat two days faster than with Regumate alone, and the weaning to oestrus interval with sows achieved similar statistically significant reductions.
Farrowing rate increased by over 5 per cent for sows, by 6 per cent for first-litter sows and just on 8 per cent for gilts.
Added to those benefits, for each 100 inseminations sows produced an extra 104 piglets, first-litter sows 105 and gilts an even more impressive 158. All gilt groups in the trials, including the control groups, were synchronised with Regumate. With unsynchronised gilts it is not possible to predict the correct time to inject Maprelin.
Phil Macdonald, the company's UK pig and poultry business manager, says the objective of every producer is profitable pigmeat production. "In the UK and other EU states the costs of feed, housing and labour are considerably higher than in other major pig-producing sectors of the world.
"This makes it important for UK producers to optimise management of the reproductive process. Maprelin is a valuable tool that can help with this objective."
The precision injection gun with Maprelin enables accurate delivery of the small amounts required. Gilts require a 2.0 ml dose 48 hours after their last Regumate treatment, first-litter sows a 0.5 ml dose 24 hours after weaning and multi-litter sows 2.0 ml 24 hours after weaning. Injections are intramuscular.
The solution requires no mixing, reducing the possibility for errors. Opened vials have a shelf life of 28 days and unopened vials a shelf life of two years. Sows and gilts need only one injection per parity, and the withdrawal period for meat and offal is zero days.
The publishers say that many people who prescribe veterinary medicines or who handle them (or bodily fluids that may contain them or their active metabolites) are not aware of the potential harmful effects they can have on human reproduction.
'Handling Veterinary Medicines and Pregnancy' gives up-to-date, evidence-based guidance on which drugs and methods of handling are hazardous; information on the relevant regulations relating to the safe handling of such medicines; and practical guidance on avoiding harm in veterinary practice.
Veterinary Prescriber says that once you have completed the module, you will:
understand the principles of reproductive toxicity
understand how data on the harmful effects of medicines are generated
be aware of the evidence on reproductive harm in veterinary practice
understand what practical measures to take to avoid harm
know where to find helpful information on medicines and pregnancy
For more information, visit: https://www.veterinaryprescriber.org/subscribers/
Omniotic combines three ingredients to remove ear wax and debris: a detergent, a solvent and an emulsifier. It also contains Octoxynol-9, lactic acid, salicylic acid and parabens, which Vita says have anti-fungal, anti-viral and anti-bacterial properties.
The product is sold in 120ml bottles with a transparent flexible tip designed to be comfortable even in stenosed, tender ear canals.
Omniotic can be used for regular daily cleaning, especially in predisposed breeds such as spaniels and lop-eared rabbits where ear conformation increases the risk of ear disease.
The product can also be used alongside other antibiotics or anti-fungal medications, something which Vita highlights as being especially important in rabbits, the ear canals of which are less prone to inflammation and stenosis, and for which topical treatment can be very effective.
Tara Evans, RVN and sales manager said: "Omniotic is an ear cleaner for dogs, cats and rabbits which combines features to meet the needs of owners and vets at the same time. The feedback from our customers is very positive; they are finding the soft, flexible applicator tip is easy to use and well tolerated. The unique combination of ingredients and the multi-species use means Omniotic can be used to support ear health across a wide variety of indications."
For more information and for the latest promotional offers, contact Tara Evans, via email: info@vitaanimalhealth.com, or telephone: 01256 591032.
Inigo’s abstract entitled “Predictive value of cardiac remodelling on survival in dogs with persistent atrial standstill – the UK perspective” sought to determine the survival of dogs in the United Kingdom with persistent atrial standstill (PAS) after pacemaker implantation and the prognostic value of cardiac remodelling. The Congress Programme Committee were impressed by Inigo’s innovative presentation, praising the planning and execution of the multi-centre project.
Ditte’s presentation was entitled “Evaluation of a point-of-care dot Enzyme-Linked Immunosorbent Assay to detect antibodies against canine parvovirus, distemper virus and adenovirus before revaccination”.
Her study described the findings of a prospective non-inferiority study of a point-of-care semi-quantitative titer test performed on canine serum samples and compared to gold standard analysis. Sensitivity, specificity, positive and negative predictive values of the point-of-care titer test were determined for the gold standard titer cut-offs for canine adenovirus, canine distemper virus and canine parvovirus. Ditte was commended by the Congress Programme Committee for the quality of presentation as well as the practical and clinically applicable findings of the study.
The BSAVA Congress Clinical Abstracts, including the winners’ abstracts, are now available to view in the BSAVA Library here: https://www.bsavalibrary.com/content/book/10.22233/9781913859039.
Bayer Animal Health has announced that it will launch Seresto, a new POM-V collar for cats and dogs that kills fleas and repels and kills ticks for up to eight months, in March.
According to Bayer, Seresto is the first treatment to provide repellency against ticks in both cats and dogs, and represents the fruit of a multidisciplinary effort incorporating the company's research into insecticides, polymers and veterinary parasiticides. The end result is a polymer-based collar that transfers the active ingredients to the lipid layer, from where they are spread by the animal's neutral oils.
Bayer Animal Health group product manager, Caroline Braidwood, said: "Seresto is simple to use on both cats and dogs. And because it is long lasting, it offers pet owners an alternative to those struggling to maintain a monthly routine. Bayer believes in innovation and Seresto is an enhancement to our product portfolio that meets the needs and requirements of pet owners and vets alike in the treatment of ticks and fleas."
Seresto contains two active ingredients - imidacloprid for fast action against fleas and flumethrin, which repels and kills ticks.
Caroline added: "Thanks to Seresto's unique polymer structure the active ingredients are safely locked away in the collar's matrix, and are released directly from the collar surface into the lipid layer of the animal at just the dose needed, ensuring optimal protection is sustained for up to 8 months."
Bayer says that because of its repellent (anti-feeding) effect, Seresto reduces the risk of vector-borne disease transmission - a first for cats. The company also says that because the active ingredients are stored on the inside of the polymer, it doesn't matter if the pet is shampooed and the lipid layer stripped off - the active ingredients are quickly replenished by the collar.
Seresto is odour-free and has a safety release mechanism to prevent strangulation. It is available in three sizes, Seresto Cat for cats less than 8kgs, Seresto Small Dog for dogs up to 8kgs and Seresto Large Dogs, for dogs over 8kg.
For further information about Seresto, contact your Bayer territory manager or call 01635 563000.
Eprecis injection (eprinomectin) is an broad spectrum endectocide with activity against gastrointestinal nematodes in sheep1 and goats2.
After Eprecis injection Haemonchus contortus in the abomasum in goats were reduced by 97.8%2 and Trichostrongylus colubriformis in the small intestine were reduced by 98.7%2.
In lactating dairy ewes Eprecis injection was found to be 99% effective against gastrointestinal nematodes3 and was associated with an increased milk yield of 8%4.
The bioavailability of eprinomectin after one Eprecis injection in goats is larger than that reported for eprinomectin pour on5, 6, with Eprecis injection found to be four times more efficacious than eprinomectin pour-on across four dairy goat farms7.
In sheep, the efficacy of Eprecis injection against gastrointestinal nematodes in sheep is 99.6% versus 86.1% for a pour-on formulation8.
Eprecis injection is associated with higher plasma levels of eprinomectin and has a higher efficacy compared to eprinomectin pour-on in dairy ewes naturally infected with gastrointestinal nematodes8.
This is also achieved using five times less active than a pour-on formulation8.
Eprecis injection is administered subcutaneously and there is no need to part the fleece or coat along the animal’s back.
Ceva says it has excellent syringeability9 and a low dose volume (0.1ml/10kg) to help with accurate dosing of animals.
Harry Walby, ruminant veterinary advisor at Ceva Animal Health, said: “Eprecis injection is a highly effective broad-spectrum wormer that is now available in sheep and goats, as well as cattle.
"The injectable formulation not only allows accurate dosing, but there is no subclinical dose transfer between animals.”
Eprecis injection is available in 100ml and 250ml CLAS vials.
To use the service, you order recycling boxes to suite your needs, and then place them where it will be most convenient for staff to throw the rubbish in.
Once full, you send the box back to TerraCycle via UPS.
It is then saved from incineration or landfills and recycled by TerraCycle.
Once collected, products and packaging are sorted and separated by material composition.
The separated items are then cleaned, shredded, and made into new recycled products such as outdoor furniture and decking, playgrounds, benches, or watering cans.
Hannah James, Head of Environment, Social & Governance at VetPartners said: “We started using the Zero Waste Boxes at our practices during the pandemic to recycle the large volumes of PPE being used, and they were instantly popular with practice teams.
"We’re now recycling plastic packaging, pet food packaging and medicine blister packs through TerraCycle as well, and since 2020 we’ve saved over 14 tonnes of waste from landfill and incineration.
"The Zero Waste Boxes are an important feature of our sustainability strategy, providing a solution for much of the waste generated by veterinary practice that isn’t hazardous and yet isn’t widely accepted for recycling.”
www.vetcycle.co.uk
The new tool uses aggregated data from Banfield Pet Hospital medical records to identify whether a dog has a high, medium, or low risk of having PD based on the breed size1,2,3,4,5, age, and body condition the owner has stated3,4.
It also makes oral care recommendations based on the dog's history (e.g., diet, previous extractions, halitosis), clinical signs (e.g., bleeding gums) and current dental routine (e.g., tooth brushing).
Global Petcare R&D VP at Mars Pet Nutrition, Dr. Elise Malandain said: “This new risk assessment tool will help indicate to pet owners what level of risk their pet is at for developing this disease to help inform conversations with veterinary professionals about prevention or treatment.”
https://www.uk.pedigree.com/gum-disease-risk-checker
The RCVS has launched a new College honour, the RCVS Queen's Medal.
RCVS President Col Neil Smith said: "The Queen's Medal will be the most prestigious honour that the RCVS can bestow upon a veterinary surgeon and will be reserved for those whose distinguished careers and outstanding lifetime achievements deserve wider recognition."
The honour was created following a review of the RCVS honours system, which demonstrated the need for a new aspirational award.
The RCVS wrote to the Cabinet Office last year, together with letters of support from Peers and MPs, many of whom attended the reception, to request permission to name this new honour after Her Majesty the Queen.
Col Smith said: "We are honoured that Her Majesty has supported the proposal and allowed the College to name the award after her, and express our sincere thanks to those Parliamentarians who supported our endeavour."
The first RCVS Queen's Medal will be presented at RCVS Day in July 2014. The nomination form for the Queen's Medal can be found at www.rcvs.org.uk/Queensmedal.
Ceva says Adaptil Junior has been proven to reduce night crying and whining by 86%2 and helps puppies to adapt to their new homes and unfamiliar situations in three days3, 4.
According to the company, puppies with Adaptil Junior are also less fearful and anxious during puppy classes, resulting in better long-term socialisation3.
Research carried out by the company found that over 60% of dog owners buy their dogs as puppies, with half of those questioned getting their dogs before they are three months old1.
Abigail King, product manager for Adaptil at Ceva Animal Health said: "Adopting a puppy is an exciting, yet challenging time with puppies facing stressful situations such as separation from their mother, socialisation, staying home alone and experiencing new sights, sounds and noises.
"Adaptil Junior is an effective, natural solution to help comfort newly adopted puppies and facilitate their education while helping them to learn and adapt to their new lives. This, in turn, will ensure that puppies get off to the best start in life, which will help keep rehoming numbers down."
Adaptil Junior comes in the form of a translucent blue collar which fits necks up to 37.5cm in circumference. The collar releases dog appeasing pheromone over a period of four weeks and should be worn continuously.
To support the launch of Adaptil Junior, Ceva Animal Health has introduced a puppy party marketing pack to provide puppy party organisers with the tools they need in order to stage puppy parties.
Produced in collaboration with the leading dog behaviourist, Gwen Bailey, the pack features display materials, webinars, gifts and literature including leaflets, puppy party invites and posters and is available with Adaptil Junior orders.
For more information, visit www.adaptil.com/uk.
Lynn Jo Ann Davies MRCVS first appeared before the Committee in January 2018 to face a number of charges related to two drink-driving offences, breaching the terms of her undertakings to the College as part of its Health Protocol, and being under the influence of alcohol on three occasions while she was on duty as a veterinary surgeon in December 2016.
Dr Davies admitted all five charges against her and admitted that this meant she was unfit to practise veterinary surgery and that she was guilty of disgraceful conduct in a professional respect. The Committee accepted her admissions and found, with the exception of one allegation, that her conduct was disgraceful in a professional respect.
At its first hearing the Committee having considered both aggravating and mitigating circumstances decided to postpone the hearing for six months on the basis of Dr Davies’ entering into a new set of undertakings, including one not to practise veterinary surgery and to remain abstinent from alcohol during the period of postponement.
At the second hearing, in July 2018, the Disciplinary Committee resumed its sanction inquiry decision. Dr Davies’ Counsel submitted on her behalf that Dr Davies wished to return to practise and the Committee reviewed her witness statements, documentary proof and medical records that she provided to demonstrate she had complied with the her undertakings given at the last hearing.
Stuart Drummond, Chairing the Committee and speaking on its behalf, said: "Having had the opportunity to see and hear from the respondent when she gave evidence and when she answered the questions put to her, the view formed of her current state of health was favourable. All members of the Committee considered that the account she gave of herself in the witness box was confident and they were reassured by her evidence as to how she now sets about managing her levels of stress and how she reacted to stressful incidents.
"Such concerns as the Committee had about her return to practice concerned her ability to receive support from a third party who would act as a mentor…the Committee therefore requires the Respondent to identify, within a period of one month of today’s date, a veterinary surgeon who would agree to act as her mentor. That mentor would have to be a veterinary surgeon acceptable to the College as someone suitable to act in that capacity and that mentor would have to be approved before the Respondent could resume practice.
"A further requirement of the Committee would be that the Respondent should make a disclosure to any new employer of the fact of her appearances before this Committee in January 2018 and in July 2018 and of the decisions of the Committee in relation to both such hearings. The final requirement of the Committee in this respect is that the respondent should not accept a 'sole charge position' at any time during her employment during this next period of postponement of sanction."
The Committee directed that the hearing be postponed for a further 12 months.
The BVA is also calling on Government to tighten pet import rules.
The advice follows news about a positive Brucella canis test in a rescue dog imported from Belarus in March this year.
The woman fostering the dog was hospitalised after coming into close contact with it, in the UK’s first confirmed dog-to-human transmission.
The foster animal and four pet dogs who were exposed to the disease, three of whom also tested positive, all had to be euthanised.
Data released by the Government shows a steep rise in confirmed Brucella canis cases since the start of 2020, rising from just three before that year to 107 till July this year.
The dogs were all either imported, had returned from holiday overseas, or been bred with an imported dog.
BVA is asking veterinary teams to:
British Veterinary Association President Justine Shotton said: “This recent case of Brucella canis in a foster dog is extremely tragic and highlights why vets have long raised concerns over the real and serious risks of importing ‘Trojan’ rescue dogs with unknown health histories into the UK.
“We know there is an added public health risk too, including for veterinary teams who treat and handle these animals, from contact with an infected dog’s contaminated body tissues and fluids.
"BVA continues to call on the Government to take urgent action to introduce stricter pet import measures, including mandatory pre-import testing, so we can minimise the spread of Brucella canis and other emerging diseases.
"We are also calling for the strengthening of enforcement provisions and checks on dogs brought into the country through the commercial route."
The 2021 B. canis risk view and statement by Public Health England (now UK Health Security Agency) contains vital information and recommendations for veterinary professionals: here:https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/960013/20210210_Brucella_canis_statement.pdf
BVA’s recommendations on tightening pet travel legislation: https://www.bva.co.uk/uploadedFiles/Content/News,_campaigns_and_policies/Policies/Companion_animals/BVA%20Position%20on%20Pet%20Travel%20Full.pdf
Sarah qualified from the Royal Veterinary College in 1998, gained an MSc in Clinical Oncology in 2003, the RCVS Certificate in Veterinary Dermatology in 2010 and RCVS Advanced Practitioner status in 2015. She is now the President of the British Veterinary Dermatology Study Group.
Sarah previously ran two dermatology referral services before co-founding Vet-AI, a company working on artificial intelligence and an online consultation service for pet owners, where she is now the Chief Veterinary Officer.
Sarah said: "Many diseases that are primarily non-pruritic often become pruritic when the animal develops secondary bacterial or yeast infection. These cases require a thorough dermatologic history and physical examination and successful treatment very often depends on identification of the underlying cause."
"Providing the right nutrition should also be implemented to ensure optimal levels of nutrients required for skin repair, barrier function and health. I will be including a complete pruritus work up, discussing how diet can be part of the management of this particular condition."
To register for the webinar, visit: https://vetportal.royalcanin.co.uk/cpd/webinar/
Merial has launched Supleneo flex, a nutraceutical supplement designed to be part of a Total Joint Health programme for dogs, administered once daily.
Merial says the new product supports its market position as a leading force in canine pain management, supported by the canine NSAID Previcox.
According to the company, Supleneo flex is suitable for all breeds, sizes and ages, and contains three key ingredients associated with joint health: glucosamine hydrochloride, chondroitin sulphate and mixed tocopherols (Vitamin E). It is designed to be used as part of an all-round joint care programme, alongside nutrition, weight management and exercise.
Merial says the soft chews are highly palatable and when tested against a range of competitor products, a significant difference was observed, with Supleneo flex readily taken and preferred by dogs.1
Supleneo flex is supported by printed and digital materials to help with owner education, including a waiting room video and an online information website at www.supleneoflex.co.uk for clients.
For veterinary surgeons, Merial is offering product advertising support and a loyalty programme.
For more information, telephone Merial on 0870 6000 123 or contact your Territory Manager.
Zoetis has launched a 4ml vial of the antibiotic, Convenia.
Zoetis says Convenia gives veterinary surgeons control by providing an assured injectable treatment course, relieving clients of the burden of daily dosing. This avoids missed or mistimed doses, lost tablets, or courses stopped too soon, thereby eliminating a major reason for treatment failure, non-compliance. Poor compliance is also a significant factor in the development of antimicrobial resistance.
Convenia is licensed for skin, soft tissue and urinary tract infections in dogs and cats, as well as severe gingivitis/periodontitis in dogs (as an adjunct to mechanical or surgical periodontal therapy). A 4ml vial can treat up to 40kg of bodyweight, making it appropriate for treating cats and smaller dogs.
Zoetis says that the launch of the new vial demonstrates its commitment to the 'Respect Antibiotics' campaign launched last year. The Respect Antibiotics campaign encourages careful and informed selection of appropriate antibiotic therapies for the treatment of dogs and cats.
Product Manager, Andrew Page, said; "We are committed to encouraging responsible antibiotic usage, and reducing the incidence of antibiotic resistance. Non-compliance plays a key role in the development of antibiotic resistance and we hope that by making Convenia more accessible through the introduction of a 4ml vial we can help alleviate compliance issues."
For further details about Convenia please contact your Zoetis Account Manager.